#### NAME OF THE MEDICINAL PRODUCT

Glucose B. Braun 100 mg/ml Solution for infusion

#### COMPOSITION

1000 ml of solution for infusion contain:

Glucose monohydrate 110.0 g (equivalent to glucose) (100.0 g)

Excipient: Water for injection.

#### THERAPEUTIC INDICATIONS

Administration of glucose for caloric support; therapy of hypoglycaemia; carrier solution for compatible electrolyte concentrates and medicinal products.

## **CONTRAINDICATIONS**

Hyperglycemia, not responding to insulin doses of up to 6 units insulin/hour, delirium tremens if such patients are already dehydrated, acute states of shock and collapse, metabolic acidosis, hyperhydration, pulmonary edema, acute cardiac failure.

## **UNDESIRABLE EFFECTS**

Undesirable effects are listed according to their frequencies as follows:

Not known: (cannot be estimated from the available data)

## Metabolism and nutrition disorders

Not known: Hospital-acquired hyponatremia

# Nervous system disorders

Not known: Hyponatremic encephalopathy

Hospital-acquired hyponatremia may cause irreversible brain injury and death due to the development of acute hyponatremic encephalopathy.

## **WARNINGS**

Keep out of the sight and reach of children. For single use only. Discard unused contents. Do not reconnect partially used containers. Use only if solution is clear and colourless or almost colourless and container and closure are undamaged.

# NOTE

Prescription only

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information.

B. Braun Melsungen AG, 34212 Melsungen, Germany, 01/2018



# **Document Control**& Signature Page

Title: 10 % w/v Glucose Intravenous Infusion Initiator: Roxana? Tranca

This document is signed electronically in compliance with the B. Braun electronic signature policies and procedures by following persons:

UserName: Pfleging, Petra (pflepede)

Title: HC-RA-DE08 Manager Global Regulatory Affairs Pharmaceuticals

Date: Tuesday, 14 May 2019, 10:33 W. Europe Daylight Time

Meaning: Document signed as Author

\_\_\_\_\_

UserName: Nagel, Norbert (nagenode)

Title: HC-ME-DE08C - Senior Manager Medical Scientific Affairs HC Date: Wednesday, 15 May 2019, 12:49 W. Europe Daylight Time

Meaning: Approve Document

\_\_\_\_\_